News Trodelvy-Keytruda pairing hits the spot in breast cancer Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.
News Pill that can slow breast cancer cleared for NHS use AstraZeneca's oral drug Truqap will soon be available for people with advanced breast cancer via the NHS in England, as long as testing is available.
News AZ, Daiichi get EU okay for breast cancer drug Datroway AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for Datroway, their TROP2-directed ADC for breast cancer.
News AZ grabs pair of EU approvals for top cancer drugs AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.
News Pfizer's new drug data in breast cancer draws muted response Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.
News Data cues up AZ oral SERD filing in first-line breast cancer AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
News NHS records to be harnessed in pancreatic cancer screening The NHS has started a pilot project that will sift through patient records to try to detect people at risk of pancreatic cancer.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face